MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Accueil・Liste d'Actions・Editas Medicine Inc

Editas Medicine Inc

Fermé

SecteurSoins de santé

2.03 -1.46

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.02

Max

2.12

Chiffres clés
By Trading Economics
Revenu	28M -25M
Ventes	4M 7.5M
Marge bénéficiaire	-332.984
Employés	246
EBITDA	27M -22M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+91.43% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-70M 205M
Ouverture précédente	3.49
Clôture précédente	2.03

Sentiment de l'Actualité

By Acuity

50%

151 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.33 / 1.54 Support & Résistance

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 déc. 2025, 23:49 UTC

Acquisitions, Fusions, Rachats

WiseTech to Sell Expedient to Appease Competition Regulator

30 déc. 2025, 17:12 UTC

Principaux Mouvements du Marché

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 déc. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 déc. 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 déc. 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 déc. 2025, 20:37 UTC

Résultats

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 déc. 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

30 déc. 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 déc. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 déc. 2025, 16:20 UTC

Résultats

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 déc. 2025, 16:18 UTC

Acquisitions, Fusions, Rachats

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 déc. 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 déc. 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 déc. 2025, 15:10 UTC

Acquisitions, Fusions, Rachats

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 déc. 2025, 14:24 UTC

Acquisitions, Fusions, Rachats

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 déc. 2025, 14:22 UTC

Acquisitions, Fusions, Rachats

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 déc. 2025, 14:20 UTC

Acquisitions, Fusions, Rachats

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 déc. 2025, 14:17 UTC

Acquisitions, Fusions, Rachats

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 déc. 2025, 14:16 UTC

Acquisitions, Fusions, Rachats

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 déc. 2025, 14:14 UTC

Acquisitions, Fusions, Rachats

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 déc. 2025, 14:12 UTC

Acquisitions, Fusions, Rachats

LVMH: Les Editions Croque Futur Is a French Publishing House

30 déc. 2025, 14:10 UTC

Acquisitions, Fusions, Rachats

LVMH Acquires Les Editions Croque Futur

30 déc. 2025, 13:49 UTC

Acquisitions, Fusions, Rachats

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 déc. 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 déc. 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 déc. 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 déc. 2025, 11:55 UTC

Market Talk

Résultats

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 déc. 2025, 11:47 UTC

Résultats

Acquisitions, Fusions, Rachats

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 déc. 2025, 11:35 UTC

Acquisitions, Fusions, Rachats

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

91.43% hausse

Prévisions sur 12 Mois

Moyen 4.02 USD 91.43%

Haut 5 USD

Bas 3 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.33 / 1.54Support & Résistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

151 / 374Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.